ANTI-SENSE OLIGONUCLETIDE MAPT
Patent Information
- Application Number
- ARP20250100633
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-08
- Filing Date
- 2025-03-07
- Publication Date
- 2026-09-16
Claims
This description provides MAPT antisense oligonucleotides and compositions comprising a MAPT antisense oligonucleotide. It also provides methods for using MAPT antisense oligonucleotides or compositions comprising a MAPT antisense oligonucleotide to reduce MAPT expression and / or treat a tauopathy in a subject.
1. A MAPT antisense oligonucleotide comprises a nucleic acid sequence selected from any one of the sequences with ident numbers: 1-11, 30-32, or 36-63, wherein optionally one or more nucleotides are independently modified nucleotides, and wherein optionally one or more internucleotide bonds are modified internucleotide bonds.
17. A MAPT antisense oligonucleotide comprises a sequence selected from any one of the sequences with identity numbers: 12-22, 33-35 or 64-94.
19. A pharmaceutical composition comprising the MAPT antisense oligonucleotide of any one of claims 1-18 and a pharmaceutically acceptable carrier.